A Grading System for Resected Invasive Squamous Cell Carcinoma of the Lung: A Multi-Institutional Study by the IASLC Pathology Committee

dc.contributor.authorMino-Kenudson M.
dc.contributor.authorBerezowska S.
dc.contributor.authorMinami Y.
dc.contributor.authorChen S.
dc.contributor.authorRay M.A.
dc.contributor.authorRerkpichaisuth V.
dc.contributor.authorHashisako M.
dc.contributor.authorLosmanova T.
dc.contributor.authorHayashi T.
dc.contributor.authorShim H.S.
dc.contributor.authorRighi L.
dc.contributor.authorGagné A.
dc.contributor.authorKim T.J.
dc.contributor.authorBubendorf L.
dc.contributor.authorLopez-Rios F.
dc.contributor.authorMatsubara D.
dc.contributor.authorvon der Thüsen J.
dc.contributor.authorLantuejoul S.
dc.contributor.authorRoden A.C.
dc.contributor.authorNicholson A.
dc.contributor.authorJain D.
dc.contributor.authorHan Y.
dc.contributor.authorWynes M.W.
dc.contributor.authorDacic S.
dc.contributor.authorSmeltzer M.P.
dc.contributor.authorCooper W.A.
dc.contributor.authorPapotti M.G.
dc.contributor.correspondenceMino-Kenudson M.
dc.contributor.otherMahidol University
dc.date.accessioned2025-12-13T18:18:27Z
dc.date.available2025-12-13T18:18:27Z
dc.date.issued2025-01-01
dc.description.abstractIntroduction: Tumor grading informs therapy and patient management across many organs, yet no consensus exists for grading invasive squamous cell carcinoma of the lung (LUSC). This study aimed to develop a globally applicable grading system using international cohorts. Methods: Histologic features, including tumor budding, smallest tumor nest size, nuclear size, and tumor spread through air spaces (STAS), were evaluated in two training sets comprising 262 and 427 LUSCs resected without neoadjuvant therapy from three institutions. Kaplan-Meier and Cox proportional hazards models were used to identify features associated with recurrence-free survival (RFS) and overall survival (OS). Features significant in both training sets were used to construct a grading system, which was then validated in a test set (n = 827, five institutions). Interobserver agreement was assessed among 10 pathologists on 25 cases. Results: Tumor budding (two-tier: cutoff at 10 buds per 0.785 mm<sup>2</sup>) was the only histologic feature significantly associated with both RFS and OS in multivariable analyses across both training sets. The proposed two-tier grading system—low-grade (0–9 buds), high-grade (≥10 buds)—was validated in the test set, demonstrating median RFS of 4.8 versus 1.6 years for low- versus high-grade tumors in the entire cohort and 7.2 versus 3.4 years within stage I patients. Interobserver agreement was moderate (Fleiss’ kappa = 0.524). Conclusions: The authors propose a simple, prognostically relevant grading system for resected invasive LUSC based on tumor budding. It is reproducible across international data sets and practical for routine pathology, offering a unified framework for clinical and research use.
dc.identifier.citationJournal of Thoracic Oncology (2025)
dc.identifier.doi10.1016/j.jtho.2025.09.1761
dc.identifier.eissn15561380
dc.identifier.issn15560864
dc.identifier.pmid41038316
dc.identifier.scopus2-s2.0-105023889177
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/123456789/113502
dc.rights.holderSCOPUS
dc.subjectMedicine
dc.titleA Grading System for Resected Invasive Squamous Cell Carcinoma of the Lung: A Multi-Institutional Study by the IASLC Pathology Committee
dc.typeArticle
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=105023889177&origin=inward
oaire.citation.titleJournal of Thoracic Oncology
oairecerif.author.affiliationHarvard Medical School
oairecerif.author.affiliationMayo Clinic
oairecerif.author.affiliationYale School of Medicine
oairecerif.author.affiliationUniversity of Bern
oairecerif.author.affiliationUniversité Grenoble Alpes
oairecerif.author.affiliationErasmus MC
oairecerif.author.affiliationUniversity of Tsukuba
oairecerif.author.affiliationCentre Hospitalier Universitaire Vaudois
oairecerif.author.affiliationYonsei University College of Medicine
oairecerif.author.affiliationUniversity of Pittsburgh Medical Center
oairecerif.author.affiliationUniversitätsspital Basel
oairecerif.author.affiliationSt. Jude Children's Research Hospital
oairecerif.author.affiliationUniversity of Memphis
oairecerif.author.affiliationHospital Universitario 12 de Octubre
oairecerif.author.affiliationRoyal Prince Alfred Hospital
oairecerif.author.affiliationSiriraj Hospital
oairecerif.author.affiliationJuntendo University School of Medicine
oairecerif.author.affiliationUniversità degli Studi di Torino, Scuola di Medicina
oairecerif.author.affiliationInstitut Universitaire de Cardiologie et de pneumologie de Québec - Université Laval
oairecerif.author.affiliationRoyal Brompton & Harefield NHS Foundation Trust
oairecerif.author.affiliationShanghai Chest Hospital
oairecerif.author.affiliationKyushu University Hospital
oairecerif.author.affiliationThe Catholic University of Korea Yeouido St. Mary's Hospital
oairecerif.author.affiliationNational Hospital Organization Ibarakihigashi National Hospital
oairecerif.author.affiliationInternational Association for the Study of Lung Cancer

Files

Collections